Novartis's Ilaris looks promising for gout
This article was originally published in Scrip
Novartis's injectable interleukin-1 blocker Ilaris (canakinumab) significantly reduced the rate of acute flares of gout in patients who are starting therapy with a uric acid lowering therapy compared with the anti-inflammatory colchicine, showed a Phase II study presented at the recent European League Against Rheumatism (EULAR) meeting in Rome.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.